120 related articles for article (PubMed ID: 33354811)
1. A broad analysis in clinical and in vitro models on regulator of G-protein signalling 10 regulation that is associated with ovarian cancer progression and chemoresistance.
Kucuk B; Kibar B; Cacan E
Cell Biochem Funct; 2021 Apr; 39(3):413-422. PubMed ID: 33354811
[TBL] [Abstract][Full Text] [Related]
2. Regulators of G-Protein signaling RGS10 and RGS17 regulate chemoresistance in ovarian cancer cells.
Hooks SB; Callihan P; Altman MK; Hurst JH; Ali MW; Murph MM
Mol Cancer; 2010 Nov; 9():289. PubMed ID: 21044322
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.
Cacan E; Ali MW; Boyd NH; Hooks SB; Greer SF
PLoS One; 2014; 9(1):e87455. PubMed ID: 24475290
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells.
Ali MW; Cacan E; Liu Y; Pierce JY; Creasman WT; Murph MM; Govindarajan R; Eblen ST; Greer SF; Hooks SB
PLoS One; 2013; 8(3):e60185. PubMed ID: 23533674
[TBL] [Abstract][Full Text] [Related]
5. RGS10 Regulates the Expression of Cyclooxygenase-2 and Tumor Necrosis Factor Alpha through a G Protein-Independent Mechanism.
Alqinyah M; Almutairi F; Wendimu MY; Hooks SB
Mol Pharmacol; 2018 Oct; 94(4):1103-1113. PubMed ID: 30049816
[TBL] [Abstract][Full Text] [Related]
6. Cellular deficiency in the RGS10 protein facilitates chemoresistant ovarian cancer.
Hooks SB; Murph MM
Future Med Chem; 2015 Aug; 7(12):1483-9. PubMed ID: 26293348
[TBL] [Abstract][Full Text] [Related]
7. RGS10 suppression by DNA methylation is associated with low survival rates in colorectal carcinoma.
Caldiran FY; Cacan E
Pathol Res Pract; 2022 Aug; 236():154007. PubMed ID: 35810565
[TBL] [Abstract][Full Text] [Related]
8. Regulator of G protein signaling 10: Structure, expression and functions in cellular physiology and diseases.
Almutairi F; Lee JK; Rada B
Cell Signal; 2020 Nov; 75():109765. PubMed ID: 32882407
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic regulation of RGS2 (Regulator of G-protein signaling 2) in chemoresistant ovarian cancer cells.
Cacan E
J Chemother; 2017 Jun; 29(3):173-178. PubMed ID: 28102109
[TBL] [Abstract][Full Text] [Related]
10. Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.
Altman MK; Alshamrani AA; Jia W; Nguyen HT; Fambrough JM; Tran SK; Patel MB; Hoseinzadeh P; Beedle AM; Murph MM
Cancer Lett; 2015 Dec; 369(1):175-83. PubMed ID: 26319900
[TBL] [Abstract][Full Text] [Related]
11. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
[TBL] [Abstract][Full Text] [Related]
12. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells.
Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG
J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254
[TBL] [Abstract][Full Text] [Related]
13. ZEB1 Promotes Chemoresistance to Cisplatin in Ovarian Cancer Cells by Suppressing SLC3A2.
Cui Y; Qin L; Tian D; Wang T; Fan L; Zhang P; Wang Z
Chemotherapy; 2018; 63(5):262-271. PubMed ID: 30481785
[TBL] [Abstract][Full Text] [Related]
14. MircroRNA-139 sensitizes ovarian cancer cell to cisplatin-based chemotherapy through regulation of ATP7A/B.
Xiao F; Li Y; Wan Y; Xue M
Cancer Chemother Pharmacol; 2018 May; 81(5):935-947. PubMed ID: 29594361
[TBL] [Abstract][Full Text] [Related]
15. Reduced expression of FILIP1L, a novel WNT pathway inhibitor, is associated with poor survival, progression and chemoresistance in ovarian cancer.
Kwon M; Kim JH; Rybak Y; Luna A; Choi CH; Chung JY; Hewitt SM; Adem A; Tubridy E; Lin J; Libutti SK
Oncotarget; 2016 Nov; 7(47):77052-77070. PubMed ID: 27776341
[TBL] [Abstract][Full Text] [Related]
16. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
[TBL] [Abstract][Full Text] [Related]
17. TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells.
Escalona RM; Bilandzic M; Western P; Kadife E; Kannourakis G; Findlay JK; Ahmed N
BMC Cancer; 2020 Oct; 20(1):960. PubMed ID: 33023532
[TBL] [Abstract][Full Text] [Related]
18. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
19. Regulator of G-protein signalling expression and function in ovarian cancer cell lines.
Hurst JH; Mendpara N; Hooks SB
Cell Mol Biol Lett; 2009; 14(1):153-74. PubMed ID: 18979070
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.
Song J; Yang P; Lu J
Cancer Biomark; 2020; 27(1):51-61. PubMed ID: 31683459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
